Progression-free survival (PFS) and objective response rate (ORR) in patients with liver-dominant neuroendocrine neoplasms (NENs) after 177 Lu-DOTA-TATE / TOC Intra-arterial Infusions (EANM 2026) - Sep 29, 2026 - Abstract #EP-0876; "Intra-arterial ¹⁷⁷Lu-based PRRT provides enhanced liver-targeted delivery, translating into improved intrahepatic tumor control and prolonged PFS compared with conventional intravenous approaches. While Ki-67 retains high prognostic value, its predictive utility remains limited. These findings support intra-arterial PRRT as a novel, potentially superior strategy for patients with liver-dominant NENs and warrant prospective validation."
Clinical • Endocrine Cancer • Hepatocellular Cancer • Liver Cancer • Neuroendocrine Neoplasm • Solid Tumor • SSTR
|
|
G. Limouris 1, 2; M. Paphiti 1; M. B. Dolgushin 3; V. Krylov 4; A. Zafeirakis 2
|